Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

Refractive errors and refractive surgery.

BIBLIOGRAPHIC SOURCE(S)

  • American Academy of Ophthalmology Refractive Management/Intervention Panel. Refractive errors & refractive surgery. San Francisco (CA): American Academy of Ophthalmology; 2007. 70 p. [469 references]

GUIDELINE STATUS

This is the current release of the guideline.

It updates a previous version: American Academy of Ophthalmology Refractive Errors Panel. Refractive errors. San Francisco (CA): American Academy of Ophthalmology; 2002. 53 p. [297 references]

All Preferred Practice Patterns are reviewed by their parent panel annually or earlier if developments warrant and updated accordingly. To ensure that all Preferred Practice Patterns are current, each is valid for 5 years from the "approved by" date unless superseded by a revision.

BRIEF SUMMARY CONTENT

 
RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

Ratings of importance to the care process (A-C) and ratings of strength of evidence (I-III) are defined at the end of the "Major Recommendations" field.

Diagnosis

The evaluation of refractive errors requires an assessment of both the refractive status of the eye, the patient's current mode of correction, symptoms, and visual needs. [A:III]

History

The history should incorporate the elements of the comprehensive adult medical eye evaluation in order to consider the patient's visual needs and any ocular pathology [A:III]

Examination

Distance visual acuity should be measured separately for each eye with current correction. [A:III]

The refraction of each eye should be evaluated independently, either objectively by retinoscopy, with an autorefractor, or with a wavefront analyzer; or it may be done subjectively. [A:III] In cooperative patients, subjective refinement of refraction using a phorometer or trial lens set is preferred. [B:III] Distance refraction should be performed with accommodation relaxed. [B:III] Near vision should be measured in each eye before cycloplegia for patients with high hyperopia, presbyopia, or complaints about near vision. [B:III]

Management

Eyeglasses

Patients with low refractive errors may not require correction; small changes in refractive corrections in asymptomatic patients are generally not recommended. [A:III] Eyeglasses are the simplest and safest means of correcting a refractive error; therefore eyeglasses should be considered before contact lenses or refractive surgery. [A:III] A patient's eyeglasses and refraction should be evaluated whenever visual symptoms develop. [A:III]

Safety glasses or eye protectors are strongly recommended for individuals involved in certain sports (e.g., racquetball, squash) and hazardous activities in which there is risk of flying particles (e.g., using hammers, saws, weed trimmers) (American Academy of Pediatrics and American Academy of Ophthalmology, 2003) [A:III] They are also recommended for all individuals with good vision in only one eye. [A:III] When ocular protection is the foremost consideration, polycarbonate plastic is the material of choice, because it is much more impact resistant than regular plastic or hardened glass (Vinger et al., 1997) [A:I]

Contact Lenses

Before contact lens fitting, an ocular history including past contact lens experience should be obtained and a comprehensive medical eye evaluation should be performed (see the National Guideline Clearinghouse [NGC] summaries of the American Academy of Ophthalmology [AAO] Preferred Practice Patterns Comprehensive adult medical eye evaluation and Pediatric eye evaluations: I. Screening. II. Comprehensive ophthalmic evaluation). [A:III] Patients should be made aware that using contact lenses can be associated with the development of ocular problems, including microbial corneal ulcers that may be vision threatening, and that overnight wear of contact lenses is associated with an increased risk of ulcerative keratitis (Mondino et al., 1986; Poggio et al., 1989; Stehr-Green et al., 1987) [A:II] The increased risk of ulcerative keratitis with extended contact lens wear should be discussed with patients who are considering this modality of vision correction (Poggio et al., 1989) [A:I] Before being fitted with overnight wear contact lenses, patients should be informed of their responsibilities and the increased risks of overnight wear compared with daily wear.[A:III]

The United States Food and Drug Administration has made the following recommendations for contact lens wearers regarding proper lens care practices (U.S. Food and Drug Administration, 2007) [A:III]

  • Wash hands with soap and water, and dry (lint-free method) before handling contact lenses.
  • Wear and replace contact lenses according to the schedule prescribed by the doctor.
  • Follow the specific contact lens cleaning and storage guidelines from the doctor and the solution manufacturer.
  • Keep the contact lens case clean and replace every 3 to 6 months.
  • Remove the contact lenses and consult your doctor immediately if you experience symptoms such as redness, pain, tearing, increased light sensitivity, blurry vision, discharge, or swelling.

First-time daily-wear or extended-wear contact lens users should be checked soon after the contact lenses are initially dispensed. [A:III] Experienced contact lens users should generally be examined annually. [A:III]

Keratorefractive Surgery

Preoperative Evaluation

A comprehensive medical eye evaluation should be performed before any refractive surgery procedure. [A:III] In addition to the elements listed in the comprehensive adult medical eye evaluation (see the NGC summary of the AAO Preferred Practice Pattern Comprehensive adult medical eye evaluation), the refractive surgery examination should also include the following elements: [A:III]

  • Visual acuity without correction
  • Manifest, and where appropriate, cycloplegic refraction
  • Computerized corneal topography
  • Central corneal thickness measurement
  • Evaluation of tear film
  • Evaluation of ocular motility and alignment (Snir et al., 2003)

The patient should be informed of the potential risks, benefits, and alternatives to and among the different refractive procedures before surgery. [A:III] The informed consent process should be documented, and the patient should be given an opportunity to have all questions answered before surgery. [A:III]

Refer to the original guideline document for detailed management recommendations.

Postoperative Care

Postoperative management is integral to the outcome of any surgical procedure and is the responsibility of the operating surgeon (American Academy of Ophthalmology and American Society of Cataract and Refractive Surgery, 2000; American Academy of Ophthalmology, 2006) [A:III]

For patients undergoing refractive surgery with surface ablation techniques, postoperative examination, including slit-lamp biomicroscopy of the cornea, is advisable on the day following surgery and every 2 to 3 days thereafter until the epithelium is healed. [A:III]

For patients who have had uncomplicated laser in situ keratomileusis (LASIK) surgery, postoperative examination should be performed within 48 hours following surgery, a second visit should be performed 1 to 4 weeks postoperatively, and further visits thereafter as appropriate. [A:III]

Intraocular Refractive Surgery

Preoperative Evaluation

A comprehensive medical eye evaluation should be performed before any refractive surgery procedure. [A:III] In addition to the elements listed in the comprehensive adult medical eye evaluation (see the NGC summary of the AAO Preferred Practice Pattern Comprehensive adult medical eye evaluation), the intraocular refractive surgery examination includes the following elements in the table below.

Achieving the targeted postoperative refraction for refractive lens exchange requires measuring axial length accurately, determining corneal power, and using the most appropriate intraocular power formula for that eye. [A:III]

Table. Elements of the Intraocular Refractive Surgery Preoperative Evaluation [A:III]

Element Phakic Intraocular Lens (IOL) Implantation Refractive Lens Exchange
Computerized corneal topography Optional Yes
Central corneal thickness measurement Yes Optional
Axial length Optional* Yes
White-to-white measurement of the limbus Yes Optional
Specular microscopy/confocal microscopy Yes Optional
Anterior chamber depth Yes Yes
Pupil size Yes Yes

* The surgeon should be prepared to implant a pseudophakic IOL in the case that there is significant damage to the lens during phakic lens implantation.

Refer to the original guideline document for detailed management recommendations.

Postoperative Care

Components of each postoperative examination should include: [A:III]

  • Interval history, including use of postoperative medications, new symptoms, and self-assessment of vision
  • Measurement of visual function (e.g., visual acuity, pinhole testing)
  • Measurement of intraocular pressure
  • Slit-lamp biomicroscopy
  • Counseling/education
  • Management plan

Provider

Patients with refractive errors should be examined and evaluated for treatment by an ophthalmologist or an optometrist. [A:III] Surgical treatment of refractive errors, including excimer laser surgery, should be performed only by an appropriately trained ophthalmologist. [A:III]

Counseling/Referral

Any decisions about surgical correction of a refractive error should be made by an informed patient and an ophthalmologist familiar with refractive surgery. [A:III] Information and discussion about the planned procedure should be available sufficiently in advance of the proposed surgical date so that the patient can carefully consider the risks, benefits, and alternatives to the procedure. [A:III]

Definitions:

Rating of Importance to the Care Process

Level A, defined as most important

Level B, defined as moderately important

Level C, defined as relevant but not critical

Rating of Strength of Evidence

Level I: Includes evidence obtained from at least one properly conducted, well-designed randomized controlled trial. It could include meta-analyses of randomized controlled trials.

Level II: Includes evidence obtained from the following:

  • Well-designed controlled trials without randomization
  • Well-designed cohort or case-control analytic studies, preferably from more than one center
  • Multiple-time series with or without the intervention

Level III: Includes evidence obtained from one of the following:

  • Descriptive studies
  • Case reports
  • Reports of expert committees/organization (e.g., Preferred Practice Patterns [PPP] Panel consensus with external peer review)

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

REFERENCES SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is identified and graded for selected recommendations (see "Major Recommendations").

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • American Academy of Ophthalmology Refractive Management/Intervention Panel. Refractive errors & refractive surgery. San Francisco (CA): American Academy of Ophthalmology; 2007. 70 p. [469 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

1997 Sep (revised 2007 Sep)

GUIDELINE DEVELOPER(S)

American Academy of Ophthalmology - Medical Specialty Society

SOURCE(S) OF FUNDING

American Academy of Ophthalmology without commercial support

GUIDELINE COMMITTEE

Refractive Management/Intervention Panel; Preferred Practice Patterns Committee

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Members of the Refractive Management/Intervention Panel: Stephen D. McLeod, MD, Chair; Roy S. Chuck, MD, PhD; D. Rex Hamilton, MD; James A. Katz, MD; Srilata S. Naidu, MD, Contact Lens Association of Ophthalmologists Representative; Allan R. Rutzen, MD, FACS; John A. Vukich, MD, American Society of Cataract and Refractive Surgery Representative; Susan Vitale, PhD, MHS, Methodologist

Members of the Preferred Practice Patterns Committee: Sid Mandelbaum, MD, Chair; Emily Y. Chew, MD; Linda M. Christmann, MD; Douglas E. Gaasterland, MD; Samuel Masket, MD; Stephen D. McLeod, MD; Christopher J. Rapuano, MD; Donald S. Fong, MD, MPH, Methodologist

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

These authors have disclosed the following financial relationships occurring from January 2006 to August 2007:

Stephen D. McLeod, MD: Alcon Laboratories, Inc. – Consultant/Advisor, Lecture fees, Grant support; Insite Vision, Inc. – Consultant/Advisor; Visiogen, Inc. – Consultant/Advisor, Lecture fees, Equity owner, Grant support.

Roy S. Chuck, MD: Alcon Laboratories, Inc., Allergan, Inc., IOP, Ista Pharmaceuticals – Lecture fees; WMR Biomedical – Consultant/Advisor.

John A. Vukich MD: AcuFocus, Inc., Lenstec, Inc. – Grant support; Advanced Medical Optics, STAAR Surgical Co., Visiogen, Inc. – Consultant/Advisor; Carl Zeiss Meditec – Lecture fees.

GUIDELINE STATUS

This is the current release of the guideline.

It updates a previous version: American Academy of Ophthalmology Refractive Errors Panel. Refractive errors. San Francisco (CA): American Academy of Ophthalmology; 2002. 53 p. [297 references]

All Preferred Practice Patterns are reviewed by their parent panel annually or earlier if developments warrant and updated accordingly. To ensure that all Preferred Practice Patterns are current, each is valid for 5 years from the "approved by" date unless superseded by a revision.

GUIDELINE AVAILABILITY

Electronic copies: Available from the American Academy of Ophthalmology (AAO) Web site.

Print copies: Available from American Academy of Ophthalmology, P.O. Box 7424, San Francisco, CA 94120-7424; telephone, (415) 561-8540.

AVAILABILITY OF COMPANION DOCUMENTS

PATIENT RESOURCES

None available

NGC STATUS

This summary was completed by ECRI on December 1, 1998. The information was verified by the guideline developer on January 11, 1999. This summary was updated on March 12, 2003. The updated information was verified by the guideline developer on April 2, 2003. This NGC summary was updated by ECRI Institute on February 6, 2008. The updated information was verified by the guideline developer on February 27, 2008.

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. Information about the content, ordering, and copyright permissions can be obtained by calling the American Academy of Ophthalmology at (415) 561-8500.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo